Skip to main content

MOTS-c vs Tirzepatide

Both MOTS-c and Tirzepatide are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

Tirzepatide

Evidence A+

Tirzepatide (Mounjaro / Zepbound)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

View full Tirzepatide profile →

Side-by-Side

AttributeMOTS-cTirzepatide
Evidence GradeBA+
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsFDA-approved for weight management and type 2 diabetes
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)2.5–15 mg weekly (subcutaneous injection)
Clinics Indexed221,850
Categoriesmetabolic, longevityweight-loss, metabolic

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — Tirzepatide

  • Superior weight loss
  • Dual hormone targeting
  • Blood sugar control
  • Reduced cardiovascular risk

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons